4D Molecular Therapeutics, Inc.
FDMT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $37 | $20,723 | $3,129 | $18,038 |
| % Growth | -99.8% | 562.3% | -82.7% | – |
| Cost of Goods Sold | $0 | $97,096 | $80,253 | $61,360 |
| Gross Profit | $37 | -$76,373 | -$77,124 | -$43,322 |
| % Margin | 100% | -368.5% | -2,464.8% | -240.2% |
| R&D Expenses | $141,299 | $97,096 | $80,253 | $61,360 |
| G&A Expenses | $46,579 | $36,494 | $32,908 | $28,011 |
| SG&A Expenses | $46,579 | $36,494 | $32,908 | $28,011 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$97,096 | -$80,253 | -$61,360 |
| Operating Expenses | $187,878 | $36,494 | $32,908 | $28,011 |
| Operating Income | -$187,841 | -$112,867 | -$110,032 | -$71,333 |
| % Margin | -507,678.4% | -544.6% | -3,516.5% | -395.5% |
| Other Income/Exp. Net | $26,973 | $12,030 | $2,538 | $16 |
| Pre-Tax Income | -$160,868 | -$100,837 | -$107,494 | -$71,317 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$160,868 | -$100,837 | -$107,494 | -$71,317 |
| % Margin | -434,778.4% | -486.6% | -3,435.4% | -395.4% |
| EPS | -2.98 | -2.58 | -3.12 | -2.46 |
| % Growth | -15.5% | 17.3% | -26.8% | – |
| EPS Diluted | -2.98 | -2.58 | -3.12 | -2.46 |
| Weighted Avg Shares Out | 53,944 | 39,130 | 32,351 | 27,730 |
| Weighted Avg Shares Out Dil | 53,944 | 39,130 | 32,351 | 27,730 |
| Supplemental Information | – | – | – | – |
| Interest Income | $27,050 | $12,211 | $2,573 | $137 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $6,705 | $4,204 | $2,403 | $1,523 |
| EBITDA | -$181,136 | -$108,663 | -$107,629 | -$69,810 |
| % Margin | -489,556.8% | -524.4% | -3,439.7% | -387% |